-
1.
公开(公告)号:US20200277252A1
公开(公告)日:2020-09-03
申请号:US16753035
申请日:2018-10-04
申请人: Meredeth Ann McGowan , Abdelghani Achab , Xavier Fradera , Yongxin Han , Derun Li , Jongwon Lim , Kun Liu , Nunzio Sciammetta , Catherine M. White , Wensheng Yu , Hongjun Zhang , Hua Zhou , MERCK SHARP & DOHME CORP.
发明人: Meredeth Ann McGowan , Abdelghani Achab , Xavier Fradera , Yongxin Han , Derun Li , Jongwon Lim , Kun Liu , Nunzio Sciammetta , Catherine M. White , Wensheng Yu , Hongjun Zhang , Hua Zhou
IPC分类号: C07C237/42 , C07D241/24 , C07D213/82 , C07D233/90 , C07D263/34 , C07D231/14 , C07D277/56 , C07D239/28 , C07D213/75 , C07D309/14 , C07D237/20 , C07D307/14 , C07D205/04 , C07D285/06 , C07D487/04
摘要: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.
-
公开(公告)号:US11319283B2
公开(公告)日:2022-05-03
申请号:US16753035
申请日:2018-10-04
申请人: MERCK SHARP & DOHME CORP. , Meredeth Ann McGowan , Abdelghani Achab , Xavier Fradera , Yongxin Han , Derun Li , Jongwon Lim , Kun Liu , Nunzio Sciammetta , Catherine M. White , Wensheng Yu , Hongjun Zhang , Hua Zhou
发明人: Meredeth Ann McGowan , Abdelghani Achab , Xavier Fradera , Yongxin Han , Derun Li , Jongwon Lim , Kun Liu , Nunzio Sciammetta , Catherine M. White , Wensheng Yu , Hongjun Zhang , Hua Zhou
IPC分类号: C07D205/04 , C07C237/42 , C07D213/75 , C07D213/82 , C07D231/14 , C07D233/90 , C07D237/20 , C07D239/28 , C07D241/24 , C07D263/34 , C07D277/56 , C07D285/06 , C07D307/14 , C07D309/14 , C07D487/04
摘要: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.
-
公开(公告)号:US10336733B2
公开(公告)日:2019-07-02
申请号:US15767371
申请日:2016-11-28
申请人: Merck Sharp & Dohme Corp. , Yongxin Han , Jongwon Lim , Satyanarayana Tummanapalli , Phieng Siliphaivanh , Kerrie Spencer
IPC分类号: C07D417/06 , C07D413/06 , C07D311/22 , C07D405/06 , A61K31/353 , A61K9/20
摘要: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene B4 receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene B4 receptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Non-alcoholic fatty liver disease/nonalcoholic steatoepatitis, metabolic syndrome, atherosclerosis, and cancer.
-
公开(公告)号:US20180305342A1
公开(公告)日:2018-10-25
申请号:US15767371
申请日:2016-11-28
申请人: Yongxin HAN , Jongwon LIM , Phieng SILIPHAIVANH , Kerrie SPENCER , Satyanarayana TUMMANAPALLI , Merck Sharp & Dohme Corp.
IPC分类号: C07D405/06 , C07D311/22 , C07D417/06 , C07D413/06
CPC分类号: C07D405/06 , A61K9/2054 , A61K31/353 , C07D311/22 , C07D413/06 , C07D417/06
摘要: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof are antagonists of leukotriene B4 receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene B4 receptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension. Non-alcoholic fatty liver disease/nonalcoholic steatoepatitis metabolic syndrome, atherosclerosis, and cancer.
-
公开(公告)号:US10329295B2
公开(公告)日:2019-06-25
申请号:US15557203
申请日:2016-03-07
申请人: MERCK SHARP & DOHME CORP. , Jongwon Lim , Michael D. Altman , Jason D. Brubaker , Craig R. Gibeau
IPC分类号: C07D487/04 , A61K31/519 , A61K31/53 , A61K45/06 , C07D403/14 , A61P29/00
摘要: The present invention relates to pyrrolotriazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
-
公开(公告)号:US10329294B2
公开(公告)日:2019-06-25
申请号:US15557197
申请日:2016-03-07
申请人: MERCK SHARP & DOHME CORP. , Jongwon Lim , Michael D. Altman , Jason D. Brubaker , Craig R. Gibeau
IPC分类号: A61K31/519 , C07D487/04 , A61K31/4162 , C07D519/00 , A61K31/55 , A61K31/551 , A61K31/553 , A61K45/06 , A61P29/00
摘要: The present invention relates to pyrazolopyrimidine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
-
公开(公告)号:US09932350B2
公开(公告)日:2018-04-03
申请号:US15515377
申请日:2015-09-25
申请人: MERCK SHARP & DOHME CORP. , Craig R. Gibeau , Solomon D. Kattar , Charles A. Lesburg , Jongwon Lim , John K. F. Maclean , Umar F. Mansoor , Alan B. Northrup , John M. Sanders , Graham F. Smith
发明人: Michael D. Altman , Jason D. Brubaker , Matthew L. Childers , Anthony Donofrio , Thierry Fischmann , Craig R. Gibeau , Solomon D. Kattar , Charles A. Lesburg , Jongwon Lim , John K. F. Maclean , Umar F. Mansoor , Alan B. Northrup , John M. Sanders , Graham F. Smith
IPC分类号: C07D491/08 , C07D239/94 , A61K31/517 , A61K45/06 , C07D239/88 , A61K31/5377 , C07D403/12 , C07D401/12 , C07D413/12 , A61K31/538 , C07D491/052 , A61K31/5386 , C07D491/048 , A61K31/55 , C07D405/12
CPC分类号: C07D491/08 , A61K31/517 , A61K31/5377 , A61K31/538 , A61K31/5386 , A61K31/55 , A61K45/06 , A61P29/00 , A61P35/00 , C07D239/88 , C07D239/94 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , C07D491/048 , C07D491/052 , C07D498/08 , A61K2300/00
摘要: The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
-
公开(公告)号:US20150266895A1
公开(公告)日:2015-09-24
申请号:US14431462
申请日:2013-09-26
申请人: Kevin J. WILSON , David J. WITTER , Phieng SILIPHAIVANH , Kathryn KIPFORD , David SLOMAN , Danielle FALCONE , Brendan O'BOYLE , Umar Faruk MANSOOR , Jongwon LIM , Joey L. METHOT , Christopher BOYCE , Lei CHEN , Matthew H. DANIELS , Salem FEVRIER , Xianhai HUANG , Ravi KURUKULASURIYA , Ling TONG , Wei ZHOU , Joseph KOZLOWSKI , Milana M. MALETIC , Bidhan A. SHINKRE , Jayanth Thiruvellore THATAI , Raman Kumar BAKSHI , Ganesh Babu KARUNAKARAN , MERCK SHARP & DOHME CORP.
发明人: Kevin J. Wilson , David J. Witter , Phieng Siliphaivanh , Kathryn Lipford , David Sloman , Danielle Falcone , Brendan O'Boyle , Umar Faruk Mansoor , Jongwon Lim , Joey L. Methot , Christopher Boyce , Lei Chen , Matthew H. Daniels , Salem Fevrier , Xianhai Huang , Ravi Kurukulasuriya , Ling Tong , Wei Zhou , Joseph Kozlowski , Milana M. Maletic , Bidhan A. Shinkre , Jayanth Thiruvellore Thatai , Raman Kumar Bakshi , Ganesh Babu Karunakaran
IPC分类号: C07D498/18 , A61K31/437 , A61K31/5377 , A61K31/496 , A61K45/06 , A61K31/4375 , C07D498/14 , A61K31/553 , C07D519/00 , C07D471/04 , C07D471/14
CPC分类号: C07D498/18 , A61K31/437 , A61K31/4375 , A61K31/496 , A61K31/5377 , A61K31/553 , A61K45/06 , C07D471/04 , C07D471/14 , C07D471/16 , C07D498/14 , C07D498/16 , C07D519/00 , A61K2300/00
摘要: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).
摘要翻译: 公开了式(1)的ERK抑制剂及其药学上可接受的盐。 还公开了使用式(1)的化合物治疗癌症的方法。
-
公开(公告)号:US20210206796A1
公开(公告)日:2021-07-08
申请号:US16771814
申请日:2018-12-17
申请人: Brian M. ANDRESEN , Frank BENNETT , Wonsuk CHANG , Matthew Lloyd CHILDERS , Jared N. CUMMING , Jongwon LIM , Min LU , Benjamin Wesley TROTTER , Wen-Lian WU , Merck Sharp & Dohme Corp.
发明人: Brian M. Andresen , Frank Bennett , Wonsuk Chang , Matthew Lloyd Childers , Jared N. Cumming , Jongwon Lim , Min Lu , Benjamin Wesley Trotter , Wen-Lian Wu
摘要: A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Za, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, R8a and R9 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
-
公开(公告)号:US10040798B2
公开(公告)日:2018-08-07
申请号:US15557201
申请日:2016-03-07
申请人: MERCK SHARP & DOHME CORP. , Jongwon Lim , Michael D. Altman , Jason D. Brubaker , Craig R. Gibeau
IPC分类号: C07D487/04 , A61K45/06 , A61K31/55 , C07D519/00 , A61K31/551 , A61K31/5025
摘要: The present invention relates to pyrrolopyridazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
-
-
-
-
-
-
-
-
-